Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
<b>Results:</b> At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab.<b>Conclusion:</b> Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.
Authors
- Manfredi Magliulo (ORCID: https://orcid.org/0000-0003-0154-3173)
- Martina Maurelli (ORCID: https://orcid.org/0000-0001-7492-8010)
- Simone Ribero (ORCID: https://orcid.org/0000-0002-0098-1406)
- Massimo Gola (ORCID: https://orcid.org/0009-0003-8536-3766)
- Maddalena Napolitano (ORCID: https://orcid.org/0000-0003-3309-8190)
- Maria Esposito (ORCID: https://orcid.org/0000-0002-4773-6993)
- Luigi Gargiulo (ORCID: https://orcid.org/0000-0002-6051-1676)
- Giampiero Girolomoni (ORCID: https://orcid.org/0000-0001-8548-0493)
- Mariateresa Rossi (ORCID: https://orcid.org/0000-0002-5101-159X)
- Bianca Maria Piraccini (ORCID: https://orcid.org/0000-0001-6537-9689)
- Carlotta Gurioli (ORCID: https://orcid.org/0000-0003-1279-7451)
- Piergiorgio Malagoli (ORCID: https://orcid.org/0000-0002-6181-6922)
- Fabrizio Amoruso
- Paola Savoia (ORCID: https://orcid.org/0000-0002-1636-8411)
- Mario Bruno Guanti (ORCID: https://orcid.org/0000-0001-5303-3517)
- Antonio Costanzo (ORCID: https://orcid.org/0000-0001-9697-2557)
- Anna Balato (ORCID: https://orcid.org/0000-0001-5485-0172)
- Maria Concetta Fargnoli (ORCID: https://orcid.org/0000-0002-7249-2556)
- Stefano Caccavale (ORCID: https://orcid.org/0000-0001-7433-9283)
- Luciano Ibba (ORCID: https://orcid.org/0000-0002-7876-4866)
- Michela Ortoncelli (ORCID: https://orcid.org/0009-0002-6774-7080)
- Ângela Alfano
- Elena Pezzolo (ORCID: https://orcid.org/0000-0003-0121-4812)
- Cataldo Patruno (ORCID: https://orcid.org/0000-0001-8661-2822)
- Anna Graziella Burroni (ORCID: https://orcid.org/0000-0003-0021-911X)
- Pietro Morrone
- Claudio Sciarrone
- Federica Veronese (ORCID: https://orcid.org/0000-0001-6438-5171)
- Caterina Foti (ORCID: https://orcid.org/0000-0001-6196-9788)
- Silvia Mariel Ferrucci (ORCID: https://orcid.org/0000-0002-6734-1366)
- Alessandra Narcisi (ORCID: https://orcid.org/0000-0002-1938-8581)
- Francesca Barei (ORCID: https://orcid.org/0000-0002-7188-7310)
- Benedetta Tirone
- Piergiacomo Calzavara-Pinton
- Maria L. Musumeci
- Marco Vaccino
Institutions
- University of Verona (IT)
- University of Modena and Reggio Emilia (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Humanitas University (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of L'Aquila (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Magna Graecia University (IT)
- University of Catania (IT)
- IRCCS Policlinico San Donato (IT)
- Azienda Ospedaliera di Cosenza (IT)
- Azienda USL di Bologna (IT)
- Ospedale Policlinico San Martino (IT)
- Ospedale San Bortolo (IT)
- IRCCS Humanitas Research Hospital (IT)
- Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
- University of Florence (IT)
- University of Turin (IT)
- University of Bari Aldo Moro (IT)
- University of Naples Federico II (IT)
- University of Brescia (IT)
- University of Genoa (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1080/09546634.2024.2411855
- Citations
- 7
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.74